Clinical Trial Update: Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Fruquintinib as second-line therapy after immune checkpoint inhibitors in unresectable hepatocellular carcinoma; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Status: RECRUITING